6 results match your criteria: "1 Department of Immunology and Institute for Cellular and Molecular Medicine[Affiliation]"

Identifying mutations that cause cystic fibrosis (CF) is important for making an early, unambiguous diagnosis, which, in turn, is linked to better health and a greater life expectancy. In patients of African descent, a molecular diagnosis is often confounded by the fact that the majority of investigations undertaken to identify causative mutations have been conducted on European populations, and CF-causing mutations tend to be population specific. We undertook a survey of published data with the aim of identifying causative CF mutations in patients of African descent in the Americas.

View Article and Find Full Text PDF

Pharmacogenetic comparison of CYP2D6 predictive and measured phenotypes in a South African cohort.

Pharmacogenomics J

November 2016

Division of Clinical Pharmacology, Toxicology & Innovative Therapeutics, Children's Mercy, and School of Medicine, University of Missouri-Kansas City, Kansas City, MO, USA.

The relationship between genetic variation in CYP2D6 and variable drug response represents a potentially powerful pharmacogenetic tool. However, little is known regarding this relationship in the genetically diverse South African population. The aim was therefore to evaluate the relationship between predicted and measured CYP2D6 phenotype.

View Article and Find Full Text PDF

Progresses towards safe and efficient gene therapy vectors.

Oncotarget

October 2015

Research Center for Functional Genomics, Biomedicine and Translational Medicine, University of Medicine and Pharmacy "Iuliu Haţieganu", Cluj Napoca, Romania.

The emergence of genetic engineering at the beginning of the 1970's opened the era of biomedical technologies, which aims to improve human health using genetic manipulation techniques in a clinical context. Gene therapy represents an innovating and appealing strategy for treatment of human diseases, which utilizes vehicles or vectors for delivering therapeutic genes into the patients' body. However, a few past unsuccessful events that negatively marked the beginning of gene therapy resulted in the need for further studies regarding the design and biology of gene therapy vectors, so that this innovating treatment approach can successfully move from bench to bedside.

View Article and Find Full Text PDF

Unlabelled: Gene-engineered CD34(+) hematopoietic stem and progenitor cells (HSPCs) can be used to generate an HIV-1-resistant immune system. However, a certain threshold of transduced HSPCs might be required for transplantation into mice for creating an HIV-resistant immune system. In this study, we combined CCR5 knockdown by a highly efficient microRNA (miRNA) lentivector with pretransplantation selection of transduced HSPCs to obtain a rather pure population of gene engineered CD34(+) cells.

View Article and Find Full Text PDF

Kafirin, the sorghum prolamin protein, like its maize homologue zein, can be made into microparticles and films and potentially used as a biomaterial. Zein has good bio- and cyto-compatibility. Kafirin could be advantageous as it is more hydrophobic, more crosslinked, more slowly digested by mammalian proteases than zein and is non-allergenic.

View Article and Find Full Text PDF

Special Issue - Pharmacogenomics & personalized medicine, Journal of Applied and Translational Genomics.

Appl Transl Genom

December 2013

Department of Immunology and Institute for Cellular and Molecular Medicine, Faculty of Health Sciences, University of Pretoria, Pretoria, South Africa.

View Article and Find Full Text PDF